Biotechnology Dupixent (dupilumab) is already a blockbuster drug, generating revenues of around $6 billion in 2021 for French pharma major Sanofi and US biotech Regeneron. But now, with its recent submission to the US Food and Drug Administration for a new indication, eosinophilic esophagitis (EoE), analysts suggest it could add nearly a further $1 billion to sales. 2 March 2022